GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Giant Biogene Holding Co Ltd (HKSE:02367) » Definitions » Net Current Asset Value

Giant Biogene Holding Co (HKSE:02367) Net Current Asset Value : HK$5.17 (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Giant Biogene Holding Co Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Giant Biogene Holding Co's net current asset value per share for the quarter that ended in Jun. 2024 was HK$5.17.

The historical rank and industry rank for Giant Biogene Holding Co's Net Current Asset Value or its related term are showing as below:

HKSE:02367' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 8.87   Med: 10.26   Max: 13.39
Current: 9.99

During the past 5 years, the highest Price-to-Net-Current-Asset-Value Ratio of Giant Biogene Holding Co was 13.39. The lowest was 8.87. And the median was 10.26.

HKSE:02367's Price-to-Net-Current-Asset-Value is ranked worse than
74.42% of 985 companies
in the Consumer Packaged Goods industry
Industry Median: 4.71 vs HKSE:02367: 9.99

Giant Biogene Holding Co Net Current Asset Value Historical Data

The historical data trend for Giant Biogene Holding Co's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Giant Biogene Holding Co Net Current Asset Value Chart

Giant Biogene Holding Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Current Asset Value
0.91 0.11 0.72 2.51 3.93

Giant Biogene Holding Co Semi-Annual Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Current Asset Value Get a 7-Day Free Trial - 2.51 3.04 3.93 5.17

Competitive Comparison of Giant Biogene Holding Co's Net Current Asset Value

For the Household & Personal Products subindustry, Giant Biogene Holding Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Giant Biogene Holding Co's Price-to-Net-Current-Asset-Value Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Giant Biogene Holding Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Giant Biogene Holding Co's Price-to-Net-Current-Asset-Value falls into.



Giant Biogene Holding Co Net Current Asset Value Calculation

Giant Biogene Holding Co's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(A: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(4522.862-658.486-9.746-0)/981.638
=3.93

Giant Biogene Holding Co's Net Current Asset Value (NCAV) per share for the quarter that ended in Jun. 2024 is calculated as

Net Current Asset Value Per Share(Q: Jun. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(7200.149-1944.015-5.077-0)/1014.86
=5.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Giant Biogene Holding Co  (HKSE:02367) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Giant Biogene Holding Co Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Giant Biogene Holding Co's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Giant Biogene Holding Co Business Description

Traded in Other Exchanges
N/A
Address
No. 1855, Shanglin Yuan 7th Road, Chang’an District, Shaanxi Province, Xi’an, CHN
Giant Biogene Holding Co Ltd design, develop and manufacture professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenosides technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop and manufacture multiple types of recombinant collagen and rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty and health properties such as skin repair, anti-aging, whitening, moisturizing and immunity improvement with a broad range of applications in the beauty and health sectors.
Executives
Refulgence Holding Limited 2201 Interest of corporation controlled by you
Trident Trust Company (b.v.i.) Limited 2301 Trustee
Fan Daidi
Yan Jianya 2101 Beneficial owner
Juzi Holding Co., Ltd 2101 Beneficial owner
Fan Daidi 2201 Interest of corporation controlled by you
Yan Jianya 2202 Interest of your spouse
Yi Fang Da Ji Jin Guan Li You Xian Gong Si 2102 Investment manager

Giant Biogene Holding Co Headlines

No Headlines